Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hitoshi Tsuda

Showing results (381-390 of 477) with videos related to

Pageof 48
Sort By:
In Vivo (Athens, Greece)|February 24, 2021
Grade 1 Endometrioid Carcinoma With an Area of Serous Carcinoma Less than 5% Is More Aggressive than Stage IA Pure-type Grade 1 Endometrioid CarcinomaMorikazu Miyamoto, Hitoshi Tsuda, Atsushi Sugiura, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 2, 2010
Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma StudyMasashi Takano, Toru Sugiyama, Nobuo Yaegashi, et al.
Oncology|October 4, 2018
Zone Formation of Lymphocyte Infiltration at Invasive Front as a Biomarker of Prognosis in Endometrial CarcinomasMorikazu Miyamoto, Masashi Takano, Hitoshi Tsuda, et al.
Plos One|February 19, 2013
Mouse model for ROS1-rearranged lung cancerYasuhito Arai, Yasushi Totoki, Hiroyuki Takahashi, et al.
Medical Oncology (Northwood, London, England)|November 24, 2017
Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatinHiroaki Soyama, Morikazu Miyamoto, Masashi Takano, et al.
In Vivo (Athens, Greece)|May 2, 2020
Ovarian Seromucinous Borderline Tumors Are Histologically Different from Mucinous Borderline TumorsTaira Hada, Morikazu Miyamoto, Hiroki Ishibashi, et al.
Oncology Reports|November 8, 2006
Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovaryMasashi Takano, Yoshihiro Kikuchi, Nobuo Yaegashi, et al.
Breast Cancer (Tokyo, Japan)|April 18, 2022
Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trialHitoshi Tsuda, Masafumi Kurosumi, Futoshi Akiyama, et al.
Cancer|September 14, 2012
Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancerHiroji Iwata, Norikazu Masuda, Yasuaki Sagara, et al.
Human Pathology|August 7, 2013
Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapyAkiko Miyagi Maeshima, Hirokazu Taniguchi, Junko Nomoto, et al.
Pageof 48

Showing results (381-390 of 477) with videos related to

Sort By:
Pageof 48
In Vivo (Athens, Greece)|February 24, 2021
Grade 1 Endometrioid Carcinoma With an Area of Serous Carcinoma Less than 5% Is More Aggressive than Stage IA Pure-type Grade 1 Endometrioid CarcinomaMorikazu Miyamoto, Hitoshi Tsuda, Atsushi Sugiura, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 2, 2010
Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma StudyMasashi Takano, Toru Sugiyama, Nobuo Yaegashi, et al.
Oncology|October 4, 2018
Zone Formation of Lymphocyte Infiltration at Invasive Front as a Biomarker of Prognosis in Endometrial CarcinomasMorikazu Miyamoto, Masashi Takano, Hitoshi Tsuda, et al.
Plos One|February 19, 2013
Mouse model for ROS1-rearranged lung cancerYasuhito Arai, Yasushi Totoki, Hiroyuki Takahashi, et al.
Medical Oncology (Northwood, London, England)|November 24, 2017
Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatinHiroaki Soyama, Morikazu Miyamoto, Masashi Takano, et al.
In Vivo (Athens, Greece)|May 2, 2020
Ovarian Seromucinous Borderline Tumors Are Histologically Different from Mucinous Borderline TumorsTaira Hada, Morikazu Miyamoto, Hiroki Ishibashi, et al.
Oncology Reports|November 8, 2006
Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovaryMasashi Takano, Yoshihiro Kikuchi, Nobuo Yaegashi, et al.
Breast Cancer (Tokyo, Japan)|April 18, 2022
Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trialHitoshi Tsuda, Masafumi Kurosumi, Futoshi Akiyama, et al.
Cancer|September 14, 2012
Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancerHiroji Iwata, Norikazu Masuda, Yasuaki Sagara, et al.
Human Pathology|August 7, 2013
Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapyAkiko Miyagi Maeshima, Hirokazu Taniguchi, Junko Nomoto, et al.
Pageof 48